Literature DB >> 30185589

Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.

Eugenio J Abente1, Daniela S Rajao1, Jefferson Santos2, Bryan S Kaplan1, Tracy L Nicholson1, Susan L Brockmeier1, Phillip C Gauger3, Daniel R Perez2, Amy L Vincent4.   

Abstract

Influenza A viruses in swine (IAV-S) circulating in the United States of America are phylogenetically and antigenically distinct. A human H3 hemagglutinin (HA) was introduced into the IAV-S gene pool in the late 1990s, sustained continued circulation, and evolved into five monophyletic genetic clades, H3 clades IV-A to -E, after 2009. Across these phylogenetic clades, distinct antigenic clusters were identified, with three clusters (cyan, red, and green antigenic cluster) among the most frequently detected antigenic phenotypes (Abente EJ, Santos J, Lewis NS, Gauger PC, Stratton J, et al. J Virol 90:8266-8280, 2016, https://doi.org/10.1128/JVI.01002-16). Although it was demonstrated that antigenic diversity of H3N2 IAV-S was associated with changes at a few amino acid positions in the head of the HA, the implications of this diversity for vaccine efficacy were not tested. Using antigenically representative H3N2 viruses, we compared whole inactivated virus (WIV) and live-attenuated influenza virus (LAIV) vaccines for protection against challenge with antigenically distinct H3N2 viruses in pigs. WIV provided partial protection against antigenically distinct viruses but did not prevent virus replication in the upper respiratory tract. In contrast, LAIV provided complete protection from disease and virus was not detected after challenge with antigenically distinct viruses.IMPORTANCE Due to the rapid evolution of the influenza A virus, vaccines require continuous strain updates. Additionally, the platform used to deliver the vaccine can have an impact on the breadth of protection. Currently, there are various vaccine platforms available to prevent influenza A virus infection in swine, and we experimentally tested two: adjuvanted-whole inactivated virus and live-attenuated virus. When challenged with an antigenically distinct virus, adjuvanted-whole inactivated virus provided partial protection, while live-attenuated virus provided effective protection. Additional strategies are required to broaden the protective properties of inactivated virus vaccines, given the dynamic antigenic landscape of cocirculating strains in North America, whereas live-attenuated vaccines may require less frequent strain updates, based on demonstrated cross-protection. Enhancing vaccine efficacy to control influenza infections in swine will help reduce the impact they have on swine production and reduce the risk of swine-to-human transmission.

Entities:  

Keywords:  influenza; live-attenuated; swine; vaccine

Mesh:

Substances:

Year:  2018        PMID: 30185589      PMCID: PMC6206469          DOI: 10.1128/JVI.01323-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine.

Authors:  Ryan L Vander Veen; Alan T Loynachan; Mark A Mogler; Brandon J Russell; D L Hank Harris; Kurt I Kamrud
Journal:  Vaccine       Date:  2012-01-23       Impact factor: 3.641

2.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

3.  Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine.

Authors:  Jürgen A Richt; Porntippa Lekcharoensuk; Kelly M Lager; Amy L Vincent; Christina M Loiacono; Bruce H Janke; Wai-Hong Wu; Kyoung-Jin Yoon; Richard J Webby; Alicia Solórzano; Adolfo García-Sastre
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  Identification of novel influenza A virus proteins translated from PA mRNA.

Authors:  Yukiko Muramoto; Takeshi Noda; Eiryo Kawakami; Ramesh Akkina; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

5.  Genetic reassortment of avian, swine, and human influenza A viruses in American pigs.

Authors:  N N Zhou; D A Senne; J S Landgraf; S L Swenson; G Erickson; K Rossow; L Liu; K j Yoon; S Krauss; R G Webster
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

7.  Antigenic characterization of H3N2 influenza A viruses from Ohio agricultural fairs.

Authors:  Zhixin Feng; Janet Gomez; Andrew S Bowman; Jianqiang Ye; Li-Ping Long; Sarah W Nelson; Jialiang Yang; Brigitte Martin; Kun Jia; Jacqueline M Nolting; Fred Cunningham; Carol Cardona; Jianqiang Zhang; Kyoung-Jin Yoon; Richard D Slemons; Xiu-Feng Wan
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

Review 8.  Innate and adaptive T cells in influenza disease.

Authors:  Simone Nüssing; Sneha Sant; Marios Koutsakos; Kanta Subbarao; Thi H O Nguyen; Katherine Kedzierska
Journal:  Front Med       Date:  2018-01-20       Impact factor: 9.927

Review 9.  The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza.

Authors:  Anthony DiPiazza; Katherine A Richards; Zackery A G Knowlden; Jennifer L Nayak; Andrea J Sant
Journal:  Front Immunol       Date:  2016-01-25       Impact factor: 7.561

10.  Predicting the Mutating Distribution at Antigenic Sites of the Influenza Virus.

Authors:  Hongyang Xu; Yiyan Yang; Shuning Wang; Ruixin Zhu; Tianyi Qiu; Jingxuan Qiu; Qingchen Zhang; Li Jin; Yungang He; Kailin Tang; Zhiwei Cao
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

View more
  7 in total

1.  A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.

Authors:  Xingui Tian; Shelby Landreth; Yao Lu; Kannupriya Pandey; Yan Zhou
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

2.  Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein.

Authors:  C Joaquín Cáceres; Stivalis Cardenas-Garcia; Aarti Jain; L Claire Gay; Silvia Carnaccini; Brittany Seibert; Lucas M Ferreri; Ginger Geiger; Algimantas Jasinskas; Rie Nakajima; Daniela S Rajao; Irina Isakova-Sivak; Larisa Rudenko; Amy L Vincent; D Huw Davies; Daniel R Perez
Journal:  Vaccines (Basel)       Date:  2021-06-27

Review 3.  T and B Cell Immune Responses to Influenza Viruses in Pigs.

Authors:  Barbara Holzer; Veronica Martini; Matthew Edmans; Elma Tchilian
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

4.  Substantial Antigenic Drift in the Hemagglutinin Protein of Swine Influenza A Viruses.

Authors:  Pia Ryt-Hansen; Anders Gorm Pedersen; Inge Larsen; Charlotte Sonne Kristensen; Jesper Schak Krog; Silke Wacheck; Lars Erik Larsen
Journal:  Viruses       Date:  2020-02-23       Impact factor: 5.048

5.  A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats.

Authors:  Daria Mezhenskaya; Irina Isakova-Sivak; Tatiana Kotomina; Victoria Matyushenko; Min-Chul Kim; Noopur Bhatnagar; Ki-Hye Kim; Sang-Moo Kang; Larisa Rudenko
Journal:  Biomedicines       Date:  2021-02-01

Review 6.  T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine.

Authors:  Anna Schmidt; Dennis Lapuente
Journal:  Viruses       Date:  2021-01-28       Impact factor: 5.048

7.  Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity.

Authors:  Sreeja Roy; Clare M Williams; Danushka K Wijesundara; Yoichi Furuya
Journal:  Vaccines (Basel)       Date:  2020-11-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.